At Bioctyogen, our innovative animal models, including 900+ target humanized models, 200+ CDX and 260+ PDX models, and orthotopic models, facilitate efficient efficacy evaluations of small molecule drugs and combination treatments.
on this page
Defined as low molecular weight compounds, small molecule drugs can easily penetrate cell membranes. Their advantages, including ease of oral administration, cost-effective manufacturing, and chemical stability, make them a cornerstone of pharmaceutical industry. Small molecule drugs are widely used in treating cancer, infectious diseases, neurological disorders, and metabolic conditions.
At Bioctyogen, our innovative animal models, including 900+ target humanized models, 200+ CDX and 260+ PDX models, and orthotopic models, facilitate efficient efficacy evaluations of small molecule drugs and combination treatments.
Antitumor activity of Drugs target EGFR in B-NDG mice. (A) Molecular targeted small-molecule anti-cancer drugs slightly inhibited tumor growth of BP0062 in B-NDG mice. PDX model of BP0062 was subcutaneously implanted into B-NDG mice (female, 6 week-old, n=6). Mice were grouped when tumor volume reached approximately 100 mm3, at which time they were treated with different targeted drugs and schedules indicated in panel. (B) Body weight changes during treatment. As shown in panel A, Molecular targeted small-molecule anti-cancer drugs were efficacious, demonstrating that PDX model of BP0062 can be used to establish tumor model and provide a powerful preclinical pancreatic tumor model with EGFR positive cells. Values are expressed as mean ± SEM.
Antitumor activity of gemcitabine in B-NDG mice. (A) Gemcitabine slightly inhibited tumor growth of BP0062 in B-NDG mice. PDX model of BP0062 was subcutaneously implanted into B-NDG mice (female, 6 week-old, n=6). Mice were grouped when tumor volume reached approximately 100 mm3, at which time they were treated with different targeted drugs and schedules indicated in panel. (B) Body weight changes during treatment. Values are expressed as mean ± SEM.
Antitumor activity of anti-human PD-1 antibody combined with cisplatin in B-hPD-1 mice. (A) Anti-human PD-1 antibody combined with cisplatin inhibited MC38-hPD-L1 tumor growth in B-hPD-1 mice. Murine colon cancer MC38-hPD-L1 cells (5×105) were subcutaneously implanted into homozygous B-hPD-1 mice (female, 5-8 week-old, n=8). Mice were grouped when tumor volume reached approximately 150±50 mm3, at which time they were treated with anti-human PD-1 antibodies and cisplatin with doses and schedules indicated in panel. (B) Body weight changes during treatment. As shown in panel A, combination of anti-hPD-1 antibody and the chemotherapy drug cisplatin shows more efficaciously inhibitory effects than individual groups, demonstrating that the B-hPD-1 mice provide a powerful preclinical model for in vivo evaluating combination therapy efficacy of anti-human PD-1 antibodies and chemotherapy drugs. Values are expressed as mean ± SEM.
Antitumor activity of anti-human PD-L1 antibody (Atezolizumab) combined with cisplatin in B-hPD-1 mice. (A) Anti-human PD-L1 antibody combined with cisplatin inhibited MC38-hPD-L1 tumor growth in B-hPD-1 mice. Murine colon cancer MC38-hPD-L1 cells (5×105) were subcutaneously implanted into homozygous B-hPD-1 mice (female, 5-8 week-old, n=8). Mice were grouped when tumor volume reached approximately 150±50 mm3, at which time they were treated with anti-human PD-L1 antibody and cisplatin with doses and schedules indicated in panel. (B) Body weight changes during treatment. As shown in panel A, combination of anti-hPD-L1 antibody and the chemotherapy drug cisplatin shows more efficaciously inhibitory effects than individual groups, demonstrating that the B-hPD-1 mice provide a powerful preclinical model for in vivo evaluating combination therapy efficacy of anti-human PD-L1 antibodies and chemotherapy drugs. Values are expressed as mean ± SEM.
(A) C57BL/6 mice were fed with high-fat diet (60 kcal% Fat) for 12 weeks to induce obesity. Dulaglutide (in house) was subcutaneous injection twice per week for 4 weeks after grouping. (B,C) Body weight, (D,E) blood glucose, and (F) glucose tolerance test results were shown above. (n=5 mice per group). Values are expressed as mean ± SEM. *** p<0.001, ** p<0.01. (n=8 mice per group)
C57BL/6 mice were fed with high-fat diet (60 kcal% Fat) for 12 weeks to induce obesity. Then mice were i.p. injected Vehicle or Celastrol (0.5mg/kg) once daily for 14 days. (A,B) Body weight, (C) blood glucose, (D,E) food intake and (F,G) glucose tolerance test results were shown above. Values are expressed as mean ± SEM. *** p<0.001. (n=5 mice per group).
